ZNF292
znf292 HOME

CONSERVATION



C-TERMINAL ANALYSES
DNA AND RNA SEQUENCES
RESEARCH QUESTIONS
RESULTS
RESOURCES
REFERENCES
Questions

Research Questions
Protein-Protein interactions

ZNF292 has been proposed to interact with POU1F1 and one or more members of the HP-1 complex. So far no direct interactions have been clearly demonstrated.
  1. Affinity purify ZNF292 from cell line(s) and look for binding partners
    1. Employ antibodies for suspected binding partners.
    2. Employ MS proteomic techinques to identify new partners.
  2. Create purified/imbolized ZNF292 for studing PPIs.
    1. Transfect ZNF292 and binding partners in bacterial expression system for large scale production.
    2. Reconstitue PPIs in vitro. Block with peptides from potential binding domains.
  3. Transfect ZNF292 with mutant binding domains.
Naturally occurring isoforms

GRCh38 shows ZNF292 as being composed of eight exons, the last being much larger than the others and including all 16 zinc fingers. The GTEx Portal shows 14 possible exons, but only the eight identified in GRCh38 show any significant levels of expression. The final exon shows expression levels twice as high any of the other 7 expressed exons suggesting some form alternate splicing. Early studies used a recombinant protein from a cDNA library which included only the last exon which was believed to code for the whole protein. GRCh38 shows only one naturally occurring transcript which is full-length but a computed transcript (exon 6-8) may correspond to the smaller protein. Is the full-length transcript translated and/or are there shorter length alternate transcripts? Is the protein cleaved?
  1. Use labeled RNA, cDNA or oligos for ISH on mouse brain sections.
  2. Find or make antibodies to peptides derived from different portions of ZNF292
    1. Generate ab to N-terminal of isoform 1
    2. Commercially available antibodies are directed to middle to C-term
  3. Northern blots of nuclear extracts


DNA binding

Verify the DNA binding site sequence(s) for ZNF292. Lipkin (1993) found ZNF292 zf10-12 bound to a region in the promoter of growth hormone. They used EMSA and ZNF292 fragments or mutants to verify that zf10-12 were involved. They also found a strong binding to the TRE at the promoter of MYH7. They used rat protein and oligos for the experiment. Repeat experiment using human ZNF292/oligos. ChIPSeq has been attempted on ZNF292 using GFP conjugated protein in HEK cells. The results (ENCODE) are unsatisfactory in that the two experimental trials show very little overlap. We should try again using native protein with an anti-ZNF292 antibody and a cell line more likely to be expressing higher levels of ZNF292.
  1. Repeat EMSA experiments
    1. Transfect human ZNF292 isoforms into bacterial expression system
    2. Create mutants with disabled binding sites
  2. ChipSeq data from cell line known to have higher expression levels of ZNF292, eg somatotrophs or from tissue, eg cerebellum.


Expression

What cell types express ZNF292 in the the brain? Specifically in the cerebellar cortex and hippocampus?
  1. Higher resolution staining with cell specific counter staining.
  2. Transcriptome studies.


A role in cell-type maintenance and epigenetics?

ZNF292’s closest paralog RLF has been shown to maintain CpG shores hypomethylated in a subset of promoters. ZNF292’s N-terminal is highly similar to that of RLF, but it’s zinc fingers vary considerably. Does ZNF292 perform a similar function in a different set of promoters? ILC3 cells in ZFP292-/- mouse mutants have been found to be largely missing. The mutants appear to be viable however.
  1. ZFP292-/- mutants could be used to study the impact on brain development.
  2. Sodium bisulfate sequencing of ZFP292+/-,-/- mutants and of PBMC from patients with protein truncating variants of ZNF292.


Effect of Protein Truncating mutations

Do some nonsense or frame-shift mutations escape nonsense mediated decay allowing the translation of a potentially deleterious truncated protein?
  1. Western blot with N-terminal directed antibodies from heterozygous mutants; patient-derived or gene edited cells.
  2. Note: This question has been addressed in Mirzaa, et. al. (in submission). They found similar amounts of the wt and PTV mRNA in the cells of two patients tested.
  3. Determine localization of truncated proteins. Are they imported to the nucleus or stay in the cytoplasm. How rapidly are they degraded.
Untitled Document

© 2024 WJ Sunderland, PhD "ZNF292 Oxen Dad"
contact: wjsunderland@gmail.com